Clinical Trials Logo

Primary Myelofibrosis clinical trials

View clinical trials related to Primary Myelofibrosis.

Filter by:

NCT ID: NCT02528877 Withdrawn - Clinical trials for Secondary Acute Myeloid Leukemia

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Start date: November 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with tacrolimus and sirolimus in preventing acute graft-versus-host disease during reduced intensity donor hematopoietic cell transplant in patients with myelofibrosis. Sometimes transplanted cells from a donor can attack the normal tissue of the transplant patient called graft-versus-host disease. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also reduce graft-versus-host disease by reducing inflammation and immune modulation. Giving ruxolitinib phosphate together with tacrolimus and sirolimus after transplant may prevent graft-versus-host disease.

NCT ID: NCT02469974 Withdrawn - Myelofibrosis Clinical Trials

Ruxolitinib in Combination With Autotransplant

Start date: May 2015
Phase: N/A
Study type: Interventional

To determine the safety of the approach of giving RUXOLITINIB before and after an autologous stem cell transplant, as measured by graft failure or death.

NCT ID: NCT01558778 Withdrawn - Clinical trials for Chronic Myelomonocytic Leukemia

Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

Start date: May 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies mechanical stimulation in preventing bone density loss in patients undergoing donor stem cell transplant. Mechanical stimulation may limit, prevent, or reverse bone loss, increase muscle and cardiac performance, and improve overall health

NCT ID: NCT00722254 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

Start date: June 2006
Phase: N/A
Study type: Observational

To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.